posted by mike kraft
on Wed, 2024-10-30 09:51

A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.
The study was published today in Scientific Reports and adds to the understand of the usefulness of Paxlovid in the Omicron-variant period.
..
Country / Region Tags:
General Topic Tags:
Problem, Solution, SitRep, or ?:
Groups this Group Post belongs to:
- Private group -